Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061052 | 0.87 | NAMPT (0.49) | NAMPTS1PR1 | |
| SCHEMBL4060466 | 0.86 | SMN1; SMN2 (0.56) | L3MBTL1NAMPTMEN1KMT2ANPC1 | |
| SCHEMBL4064076 | 0.79 | MEN1 (0.58) | L3MBTL1MEN1KMT2ACYP1A2NPC1 | |
| SCHEMBL4058778 | 0.78 | GAA (0.56) | L3MBTL1KMT2ACYP1A2NPC1RAB9A | |
| SCHEMBL4062636 | 0.78 | NAMPT (0.52) | NAMPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5072186 | 0.78 | NAMPT (0.53) | NAMPTS1PR1 | |
| SCHEMBL8143964 | 0.77 | PKM (0.65) | L3MBTL1MEN1KMT2ACYP1A2NPC1 | |
| SCHEMBL4068903 | 0.76 | NPC1 (0.51) | L3MBTL1MEN1KMT2ACYP1A2NPC1 | |
| SCHEMBL15921626 | 0.75 | BUB1 (0.43) | NAMPTS1PR1 | |
| SCHEMBL13946964 | 0.75 | NAMPT (0.50) | NAMPTNPC1RAB9AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | claimed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | claimed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | claimed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | claimed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | claimed |
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-6458813-B1 | 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER | AMGEN INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | disclosed |
| US-6333341-B1 | TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS | AMGEN INC. | 2001-12-25 | — | — | US | disclosed |
| US-6184237-B1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | IL1B, IL6, IL1A | L3MBTL1 2549/4885NAMPT 165/4885MEN1 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.